NCT03589729

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Recruiting now Phase 2 Last updated 20 November 2025

What this trial tests

Phase 2 trial testing Cladribine in Acute Myeloid Leukemia in 100 participants. Currently enrolling.

Timeline

19 September 2018

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	100
Start date	19 September 2018
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

• Cladribine (CLADRIBINE) — full drug profile →
• Cytarabine — full drug profile →
• Dexrazoxane Hydrochloride
• Gemtuzumab Ozogamicin (Gemtuzumab Ozogamicin) — full drug profile →
• Idarubicin (IDARUBICIN) — full drug profile →

Conditions studied

• Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
• Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive — all drugs for Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive →
• Blasts 10 Percent or More of Bone Marrow Nucleated Cells — all drugs for Blasts 10 Percent or More of Bone Marrow Nucleated Cells →
• High Risk Myelodysplastic Syndrome — all drugs for High Risk Myelodysplastic Syndrome →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

12 and older, any sex, with Acute Myeloid Leukemia or Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart from the side effects of drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin, in participants with blood cancers.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting ferroptosis opens new avenues for the development of novel therapeutics.
   Sun S, Shen J, Jiang J, Wang F, et al · · 2023 · cited 380× · PMID 37735472 · DOI 10.1038/s41392-023-01606-1
2. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer.
   Zeng Z, Fu M, Hu Y, Wei Y, et al · · 2023 · cited 93× · PMID 37853437 · DOI 10.1186/s12943-023-01877-w
3. Ferroptosis: mechanisms and therapeutic targets.
   Zhou Q, Meng Y, Le J, Sun Y, et al · · 2024 · cited 32× · PMID 39568772 · DOI 10.1002/mco2.70010
4. Harnessing ferroptosis to transform glioblastoma therapy and surmount treatment resistance.
   Singh S, Mohapatra I, Barik D, Zheng H, et al · · 2025 · cited 5× · PMID 41057317 · DOI 10.1038/s41420-025-02744-x
5. How to Treat Adult Acute Myeloid Leukemia: An Evolving Paradigm.
   Wilson NR, Pemmaraju N. · · 2021 · cited 3× · PMID 34988486 · DOI 10.1016/j.jaccao.2021.09.013
6. Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.
   Wu S, Liu H, Yin Y, Li J, et al · · 2026 · PMID 41955967 · DOI 10.1016/j.neo.2026.101306
7. Ferroptosis in cardiovascular diseases: molecular mechanisms and a novel therapeutic target.
   Yu S, Pang Z, Fang H, Liu C. · · 2026 · PMID 41795043 · DOI 10.1186/s43556-026-00420-9